IP02-01: Metabolomics analysis identifies serum biomarkers predicting risk of intravesical tumorrecurrence after intravesical Bacillus Calmette–Guérin therapy (BCG) in patients withnon-muscle invasive bladder cancer

IP02-01: Metabolomics analysis identifies serum biomarkers predicting risk of intravesical tumorrecurrence after intravesical Bacillus Calmette–Guérin therapy (BCG) in patients withnon-muscle invasive bladder cancer

Friday, May 15, 2026 7:00 AM to 9:00 AM · 1 hr. 59 min. (America/New_York)
146A
Abstract

Log in

See all the content and easy-to-use features by logging in or registering!